Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 27, 2019 (7 years ago)

25% Dextrose Injection (Dextrose Monohydrate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or expiration date.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

25% Dextrose Injection, USP 2.5 grams (250 mg/mL) 10 mL Single-dose, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-1775-10

Affected NDC 0409-1775-10

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dextrose
Dextrose monohydrate
NDC 00409-1775
250 mg/mL Injection, Solution
Intravenous
Hospira, Inc. Rx
Recalling firm
Pfizer Inc.
NDC code
0409-1775-10
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0577-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Pfizer Inc.

All 2019 recalls

Other labeling / mix-up recalls from 2019

All labeling / mix-up recalls
Class II · Moderate risk

Theraflu Cough Relief

Labeling: Label Lacks Warning: Product recalled due to absence of a warning statement on the product label, Ask a doctor before use if you have a sodium-restricted diet.

Terminated Labeling / mix-up GSK Consumer Health, Inc D-0996-2020
Class II · Moderate risk

Testosterone Topical Cream 4%

Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.

Terminated Labeling / mix-up MPRX, Inc. dba Medical Park Pharmacy D-0820-2020
Class II · Moderate risk

Tadalafil 6 mg Capsule

Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.

Terminated Labeling / mix-up MPRX, Inc. dba Medical Park Pharmacy D-0819-2020
Class II · Moderate risk

Tadalafil 20 mg Troche

Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.

Terminated Labeling / mix-up MPRX, Inc. dba Medical Park Pharmacy D-0818-2020